Dorsomorphin (Compound C): Precision AMPK and BMP Pathway Inhibition for Advanced Research

Principle Overview: Dual-Pathway Inhibition for Maximum Experimental Control

Dorsomorphin (Compound C) stands at the intersection of metabolic and developmental biology as a reversible, ATP-competitive AMPK inhibitor (Ki = 109 nM) and potent BMP signaling inhibitor. This compound, supplied by APExBIO, offers high selectivity for AMPK over related kinases and also robustly blocks BMP4-induced SMAD phosphorylation (IC₅₀ = 0.47 μM). Mechanistically, Dorsomorphin suppresses downstream targets such as acetyl-CoA carboxylase (ACC) phosphorylation by 80%, modulates autophagic proteolysis, and inhibits hepatic hepcidin gene transcription, resulting in increased serum iron levels. Its dual-action profile enables researchers to simultaneously dissect the AMPK signaling pathway and the BMP/Smad signaling cascade, supporting a wide array of cell biology, cancer research, and regenerative medicine studies.

Recent translational research, including a pivotal study published in Inflammation (Lei et al., 2025), further underscores the centrality of AMPK in controlling macrophage polarization and inflammation, highlighting the therapeutic and experimental value of precise AMPK modulation.

Experimental Workflow: Step-by-Step Protocols and Enhancements

1. Compound Preparation and Solubility Optimization

• Reconstitution: Dorsomorphin is insoluble in water and ethanol, but readily dissolves in DMSO at concentrations ≥8.49 mg/mL with gentle warming and ultrasonic agitation. Prepare stock solutions fresh to ensure maximal activity.
• Aliquoting & Storage: Store dry powder at -20°C. Avoid repeated freeze-thaw cycles for both powder and solutions. Prepare working aliquots to minimize degradation; stock solutions should be used promptly and not stored long-term.

2. Cell-Based Assays: AMPK and BMP Pathway Dissection

• AMPK Inhibition in Hepatocytes and HeLa Cells: Use 4–40 μM Dorsomorphin in cell culture. Add compound directly to culture medium containing 0.1–1% DMSO (final concentration). Incubate for 1–6 hours for acute signaling studies or up to 24 hours for metabolic readouts.
• BMP4-Induced SMAD Phosphorylation Inhibition: Pre-treat cells (e.g., neural stem cells, hESCs) with Dorsomorphin for 30–60 minutes prior to BMP4 stimulation. Analyze SMAD1/5/8 phosphorylation status via Western blot or immunofluorescence.
• Autophagy Regulation: Assess autophagic flux by measuring LC3-II accumulation and p62 turnover in the presence of Dorsomorphin. Inhibition of AMPK leads to suppressed autophagic activity.

3. Animal Models: In Vivo Pathway Modulation

• Dosing: For rodent studies, typical dosing is 10 mg/kg via intraperitoneal injection. Prepare Dorsomorphin in sterile DMSO or DMSO/saline mixture.
• Applications: Proven efficacy in reducing hepatic hepcidin mRNA (modulating iron metabolism) and in models of dorsalization (zebrafish embryos).

4. Data Collection & Analysis

• Western Blot: Quantify ACC phosphorylation, SMAD1/5/8 phosphorylation, and AMPK activity using phospho-specific antibodies. Normalize to total protein for accurate quantification.
• qRT-PCR & ELISA: Measure target gene expression (e.g., hepcidin, inflammatory cytokines) and secreted factors to confirm pathway modulation.

Advanced Applications and Comparative Advantages

1. Immunometabolic Research: Macrophage Polarization and Inflammation

The referenced study by Lei et al. (2025) demonstrates how AMPK activity directly influences M1 macrophage polarization via the JAK2/STAT3 pathway, impacting airway inflammation in obesity-related asthma (Inflammation, 2025). By deploying Dorsomorphin as an AMPK inhibitor, researchers can recapitulate these immune-metabolic shifts in vitro and in vivo, enabling the dissection of inflammatory mechanisms and identification of new therapeutic targets.

2. Autophagy Regulation and Metabolic Modeling

Dorsomorphin’s robust inhibition of AMPK-mediated autophagic proteolysis (notably suppressing ACC phosphorylation by ~80%) makes it a preferred tool for modeling metabolic stress, muscle atrophy, and cancer cell survival. As highlighted in "Dorsomorphin (Compound C): Precision AMPK and BMP Inhibition", this dual-action approach enables comprehensive studies of mitophagy, iron metabolism, and metabolic syndrome, complementing the findings in obesity-linked asthma and beyond.

3. BMP Pathway Inhibition in Stem Cell and Regenerative Biology

By blocking BMP4-induced SMAD phosphorylation, Dorsomorphin supports neural induction and self-renewal in hESCs, facilitating the generation of neural precursor populations. This function is thoroughly explored in "Dorsomorphin (Compound C): Strategic Deployment of Dual-Pathway Control", which extends the application scope to neural regeneration and stem cell engineering—demonstrating how Dorsomorphin complements and extends standard protocols for cellular differentiation.

4. Iron Metabolism Modulation and Disease Modeling

Dorsomorphin’s ability to decrease hepatic hepcidin transcription and increase serum iron provides a valuable tool for modeling iron overload disorders and studying the cross-talk between metabolic and iron homeostasis pathways. These features are further detailed in "Dorsomorphin (Compound C): Unraveling AMPK and BMP Pathways", which examines the compound’s role in immunometabolic and iron regulation contexts.

Troubleshooting and Optimization Tips

• Solubility Challenges: If Dorsomorphin fails to dissolve at desired concentrations, increase DMSO percentage (up to 100% for stock solutions), apply gentle heating (37°C), and use ultrasonic agitation. Avoid water or ethanol as solvents to prevent precipitation.
• Cytotoxicity: At concentrations >40 μM or with prolonged exposure, off-target effects or cytotoxicity may occur in sensitive cell lines. Titrate dose and minimize exposure duration; always include vehicle (DMSO-only) controls.
• Pathway Specificity: While Dorsomorphin is highly selective, confirm pathway inhibition with downstream readouts (e.g., pACC for AMPK, pSMAD1/5/8 for BMP) and complement with genetic knockdown as needed for mechanistic validation.
• Batch Consistency: Use products from reliable suppliers like APExBIO, and record lot numbers to ensure reproducibility across experiments.
• Animal Studies: Monitor for DMSO-related toxicity; dilute stocks appropriately and use proper controls to distinguish compound effects from vehicle artifacts.

Future Outlook: Extending the Boundaries of Cellular Signaling Research

The dual-inhibition strategy embodied by Dorsomorphin (Compound C) is driving innovation in multiple domains—ranging from elucidating the mechanisms of metabolic inflammation and cancer to engineering advanced stem cell differentiation protocols. As more high-content and multi-omics approaches enter the mainstream, the precise control over AMPK and BMP/Smad signaling enabled by Dorsomorphin will become increasingly indispensable for modeling complex physiological and pathological states.

Emerging research, including studies like Lei et al. (2025), position AMPK modulation as a linchpin in targeting inflammation and metabolic disease. Integrating Dorsomorphin into multi-modal experimental workflows—alongside genetic, pharmacologic, and systems biology tools—will accelerate discovery in immunometabolism, oncology, and regenerative medicine.

For those seeking additional context or in-depth strategies, the articles "Strategic Dual-Pathway Inhibition" and "Precise AMPK and BMP Pathway Interrogation" provide further evidence-based guidance for leveraging APExBIO’s Dorsomorphin portfolio in advanced research settings.

In summary: The next generation of cell signaling research demands tools capable of dissecting intersecting regulatory axes with precision. Dorsomorphin (Compound C) from APExBIO delivers this dual-action capability, empowering researchers to unravel the intricacies of the AMPK signaling pathway, BMP/Smad signaling, autophagy regulation, iron metabolism, and cellular differentiation—paving the way for new discoveries in disease modeling, therapy development, and beyond.